ArticleArthritis & rheumatology (Hoboken, N.J.)2026
Skin Transcriptomics Reveal Shared Molecular Mechanisms for Skin and Lung Involvement in Systemic Sclerosis.
Article in Arthritis & rheumatology (Hoboken, N.J.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
Abstract
objectiveSystemic sclerosis (SSc) is characterized by dysregulated immunity, microvascular damage, and progressive fibrosis. SSc-related interstitial lung disease (SSc-ILD) is the leading disease-specific cause of death; it is therefore important to identify biomarkers associated with SSc-ILD. We hypothesized that the skin transcriptome would provide mechanistic clues that could further our understanding of lung impairment in SSc-ILD.
methodsWe conducted a multistage analysis of SSc transcriptomes using weighted gene correlation analysis, gene set enrichment analysis, and single-cell RNA sequencing.
resultsWe identified seven modules correlated with skin and lung function involvement. Unsupervised clustering of these genes classified patients into two groups, one of which showed severe multiorgan involvement characterized by increased skin fibrosis and decreased lung function (P < 0.05). The KRAS pathway was enriched in the severe cluster. Deconvolution of the severe cutaneous signature in SSc skin and lungs showed increased expression in stromal cells and monocytes, whereas the KRAS pathway was enriched in stromal cells only. Profiling KRAS and downstream signaling in lungs from individuals with SSc-ILD demonstrated activation of these pathways (P < 0.05).
conclusionWe found a severe cutaneous transcriptomic signature of SSc associated with multiorgan involvement. By deconvoluting the severe cutaneous signature, we have identified pathways enriched in specific cell types, including KRAS in stromal cells and a combination of stromal and immune cells in the severe signature. The severe SSc signature can provide a framework for understanding shared mechanisms in skin and lung fibrosis and may help identify additional molecular pathways.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.